Recently, inhibition of phosphodiesterase 5 (PDE5) and HDAC has been suggested as a potent novel therapeutic approach for AD (Rabal et al., 2016; Sánchez-Arias et al., 2017; Rabal et al., 2018). The gene discussed is HDAC9; the disease is Alzheimer disease.